These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16842155)

  • 1. Discovery and development of purine-scaffold Hsp90 inhibitors.
    Chiosis G
    Curr Top Med Chem; 2006; 6(11):1183-91. PubMed ID: 16842155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purine-scaffold Hsp90 inhibitors.
    Chiosis G; Tao H
    IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of purine-scaffold small molecule inhibitors of Hsp90.
    Chiosis G; Lucas B; Huezo H; Solit D; Basso A; Rosen N
    Curr Cancer Drug Targets; 2003 Oct; 3(5):371-6. PubMed ID: 14529388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP90 inhibitors: current development and potential in cancer therapy.
    Sidera K; Patsavoudi E
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
    Wright L; Barril X; Dymock B; Sheridan L; Surgenor A; Beswick M; Drysdale M; Collier A; Massey A; Davies N; Fink A; Fromont C; Aherne W; Boxall K; Sharp S; Workman P; Hubbard RE
    Chem Biol; 2004 Jun; 11(6):775-85. PubMed ID: 15217611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.
    Vilenchik M; Solit D; Basso A; Huezo H; Lucas B; He H; Rosen N; Spampinato C; Modrich P; Chiosis G
    Chem Biol; 2004 Jun; 11(6):787-97. PubMed ID: 15217612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in the study of heat shock protein 90 inhibitors].
    Luo HM; Sun W; Yin JY; Yang XH
    Yao Xue Xue Bao; 2010 Jul; 45(7):813-20. PubMed ID: 20931776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
    Soga S; Akinaga S; Shiotsu Y
    Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
    He H; Zatorska D; Kim J; Aguirre J; Llauger L; She Y; Wu N; Immormino RM; Gewirth DT; Chiosis G
    J Med Chem; 2006 Jan; 49(1):381-90. PubMed ID: 16392823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
    Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
    J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purine-scaffold Hsp90 inhibitors.
    Taldone T; Chiosis G
    Curr Top Med Chem; 2009; 9(15):1436-46. PubMed ID: 19860732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy.
    Lattouf JB; Srinivasan R; Pinto PA; Linehan WM; Neckers L
    Nat Clin Pract Urol; 2006 Nov; 3(11):590-601. PubMed ID: 17088927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
    Xiao Y; Liu Y
    Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
    Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
    Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
    Isaacs JS
    Expert Opin Investig Drugs; 2005 Jun; 14(6):569-89. PubMed ID: 16004589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.